A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis
Authors:
- 21 December 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (1) , 132-146
Abstract
This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular assays, the compounds exhibit single-digit nanomolar potency toward VEGFR2. Compounds of this series show good exposure in rodents when dosed orally. They potently inhibit VEGF-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by ELISA for TIE-2 in lysates or by immunohistochemical analysis. This novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role.Keywords
This publication has 37 references indexed in Scilit:
- Angiogenesis in health and diseaseNature Medicine, 2003
- Vascular endothelial growth factor and its receptorsCytokine & Growth Factor Reviews, 1996
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- VEGF-mediated tumour angiogenesis: a new target for cancer therapyCurrent Opinion in Biotechnology, 1995
- Molecular Mechanisms of Developmental and Tumor AngiogenesisBrain Pathology, 1994
- Vascular permeability factor (VPF, VEGF) in tumor biologyCancer and Metastasis Reviews, 1993
- Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature, 1992
- Cancer metastasis and angiogenesis: An imbalance of positive and negative regulationCell, 1991
- Tumor Angiogenesis1985